Assertio Therapeutics(ASRT)
Assertio Therapeutics, Inc. (formerly Depomed, Inc.) is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor.
...
More
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Graph type:Clear all
Line
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Revenue
Events
Tickers
-
0.00 %
Mock data
Subscribe for the real data
Subscribe for the real data
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
Mock data
Subscribe for the real data
Subscribe for the real data
Revenue by Drug
No data
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Cambia | Diclofenac potassium | 2009-06-17 | 2026-2035 | |
| Proquin | Ciprofloxacin | 2005-05-19 | 2025-2038 | ... |
| Zipsor | Diclofenac potassium | 2009-06-16 | 2026-2035 |
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use